Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 9/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19554989 | 0.99 | TYK2 (0.42) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19554993 | 0.99 | TYK2 (0.42) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19555169 | 0.91 | TYK2 (0.44) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19555168 | 0.91 | TYK2 (0.44) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19554996 | 0.84 | NTRK1 (0.42) | TYK2PDE4DEPHX2CNR2NTRK1 | |
| SCHEMBL19554999 | 0.84 | NTRK1 (0.42) | TYK2PDE4DEPHX2CNR2NTRK1 | |
| SCHEMBL19577955 | 0.83 | NTRK1 (0.47) | EPHX2CNR2NTRK1 | |
| SCHEMBL19577953 | 0.83 | NTRK1 (0.41) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19705413 | 0.83 | NTRK1 (0.41) | TYK2PDE4DEPHX2CNR1CNR2 | |
| SCHEMBL19705456 | 0.76 | TYK2 (0.45) | TYK2PDE4DCNR1CNR2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | TYK2 873/4885PDE4D 482/4885EPHX2 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.